News archive
Showing 696 results
April 2021
-
Media Release
Novartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosis
New post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently… -
Media Release
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
-
Media Release
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment EAST HANOVER, N.J., April 12, 2021…
February 2021
-
Story Education and Awareness
Understanding Heart Health Inequities During Black History Month
After years of decline, cardiovascular disease mortality is on the rise, with a disproportionate impact on Black Americans
-
Media Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (… -
Story Global Impact
Reimagining Healthcare in Challenging Times: Novartis in Society US Report for 2020
Novartis is striving every day to help patients, strengthen communities, drive sustainability and build a more equitable healthcare system for all.
-
Story Education and Awareness
Telemedicine is helping patients in underserved communities access quality healthcare
The Novartis US Foundation partners with local groups to improve healthcare in underserved communities, including by expanding use of telemedicine.
January 2021
-
Media Release
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently… -
Statement
Novartis US response to COVID-19
